Add an ACE Inhibitor or ARB Immediately
This patient requires immediate addition of a renin-angiotensin system inhibitor (ACEi or ARB) to his current amlodipine regimen, given his advanced CKD (stage 5, eGFR 13), diabetes, and uncontrolled hypertension. 1, 2
Rationale for RAS Inhibition
Your patient has three compelling indications for ACEi/ARB therapy:
- Advanced CKD with diabetes: The 2025 AHA/ACC guidelines strongly recommend ACEi or ARB for patients with diabetes and CKD (eGFR <60) 1
- Albuminuria assessment needed: While not specified in your case, the KDIGO 2021 guidelines provide a 1B recommendation for RASi in diabetic CKD patients with moderate-to-severe albuminuria (≥30 mg/g) 2
- Cardio-renal protection: Even at eGFR 13, RASi therapy provides mortality and cardiovascular benefit unless contraindicated
Blood Pressure Target
Target BP <130/80 mm Hg based on the 2025 AHA/ACC guidelines for patients with diabetes and hypertension 1. His current BP of 158/79 requires intensification, though the diastolic is already at goal.
The systolic BP of 158 mm Hg is significantly above target. The BPROAD trial demonstrated improved cardiovascular outcomes with intensive BP control (SBP <120 mm Hg) in diabetic patients ≥50 years, though this must be balanced against his advanced CKD 1.
Specific Medication Recommendations
First: Add ACEi or ARB
- Start with standard dosing (e.g., lisinopril 10 mg daily or losartan 50 mg daily)
- Titrate to maximum tolerated dose as the proven benefits in trials were achieved with maximal dosing 2
- Monitor closely: Check serum creatinine and potassium within 2-4 weeks 2
Critical Monitoring Parameters
- Accept up to 30% creatinine rise within 4 weeks of initiation—this is hemodynamic and acceptable 2
- Manage hyperkalemia aggressively with dietary potassium restriction and potassium binders rather than stopping the RASi 2
- Only discontinue RASi if: creatinine rises >30%, symptomatic hypotension occurs, or hyperkalemia is uncontrollable despite treatment 2
Second: Optimize Diuretic Therapy
At eGFR 13, thiazide diuretics (including thiazide-like agents) have limited efficacy:
- Switch to or add a loop diuretic (e.g., furosemide 40-80 mg daily or torsemide 20-40 mg daily) 3
- Loop diuretics are mandatory at this level of renal function for volume management and BP control 3
- Consider adding the loop diuretic to amlodipine while initiating the ACEi/ARB
Third: Consider SGLT2 Inhibitor
Despite the low eGFR, initiate an SGLT2 inhibitor if not already prescribed:
- Provides cardio-renal protection independent of glycemic control 1, 4
- Can be initiated at eGFR as low as 20 ml/min/1.73 m² for cardio-renal benefits (though glycemic benefits diminish below 30)
- Modest BP-lowering effect as adjuvant therapy 4
Common Pitfalls to Avoid
Don't withhold RASi due to low eGFR: The KDIGO practice point specifically addresses this—only consider reducing or stopping at eGFR <15 if uremic symptoms develop or for uncontrolled hyperkalemia 2
Don't stop RASi for mild hyperkalemia: Use potassium binders (patiromer or sodium zirconium cyclosilicate) and dietary restriction first 2
Don't use thiazides alone at this eGFR: They are ineffective below eGFR 30; loop diuretics are required 3
Don't combine ACEi + ARB: This is explicitly contraindicated and increases adverse events without benefit 2
Don't ignore albuminuria status: Check urine albumin-to-creatinine ratio if not recently done—this guides intensity of RASi therapy 2
Practical Implementation Algorithm
Week 0:
- Add lisinopril 10 mg daily (or ARB equivalent)
- Add furosemide 40 mg daily (or switch from thiazide if on one)
- Continue amlodipine 10 mg
- Check baseline potassium and creatinine
Week 2-4:
- Recheck creatinine, potassium, BP
- If creatinine rise <30% and K+ <5.5: continue
- If BP still >130 systolic: increase lisinopril to 20 mg
Week 6-8:
- Titrate lisinopril to 40 mg if tolerated and BP not at goal
- Adjust loop diuretic dose based on volume status and BP response
Ongoing:
- Consider adding low-dose spironolactone (12.5-25 mg) if BP remains uncontrolled, but only with aggressive potassium monitoring given eGFR 13 5
- Initiate SGLT2 inhibitor for cardio-renal protection
- Prepare for renal replacement therapy given eGFR 13 (stage 5 CKD)
The combination of ACEi/ARB + CCB + loop diuretic forms the backbone of therapy for this patient, with SGLT2 inhibitor added for disease modification rather than primary BP control 1, 2, 4.